Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges toward $679.56 billion by 2030[1] driven by precision therapeutics and accelerated regulatory frameworks, while complementary advances in drug delivery systems launched at major industry events are streamlining paths to market for complex biological treatments[2]. The FDA's recent initiatives to simplify development pathways and reduce clinical testing requirements are creating favorable conditions across multiple therapeutic categories, from rare diseases to chronic conditions affecting millions[3]. These industry-wide developments are benefiting a diverse range of publicly traded biotechnology companies advancing innovative treatment platforms, including Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Axsome Therapeutics, Inc. (NASDAQ: AXSM), West Pharmaceutical Services, Inc. (NYSE: WST), and Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).
Manufacturing investments exceeding $15 billion since 2024 are building new production capacity to meet surging demand for biological therapeutics across oncology, immunology, and rare disease categories[1]. The convergence of streamlined regulatory approval processes with expanding therapeutic applications[4] positions companies developing advanced treatment platforms and essential delivery infrastructure to capitalize on what analysts project as sustained double-digit growth through the end of the decade.
Avant Technologies, Inc. (OTCQB: AVAI) has finalized a strategic transformation toward a partnership-driven business model that observers believe places the company as a contender in advanced cell-based therapeutics. Through strategic joint ventures including the newly announced Insulinova, Inc. and its established Klothonova, Inc. partnership, Avant is rapidly constructing a potentially integrated healthcare platform, developing targeted cell-based treatments for diabetes, age-related diseases, and other conditions through innovative biotechnology collaborations.
Recently Avant announced the formation of Insulinova, Inc., a paradigm-shifting joint venture with Singapore-based SGAustria Pte. Ltd. aimed at revolutionizing a diabetes treatment through innovative stem cell and encapsulation technologies. The joint venture will pursue a Research Collaboration Agreement to advance a proprietary differentiation process that achieves high-efficiency conversion of stem cells into insulin-producing and regulating cells, targeting type 1 and some insulin-dependent type 2 diabetes patients globally. Avant will provide initial funding over the next eight months to hit established criteria relevant for an efficient, sustainable, and reproducible diabetes treatment, while leveraging its resources to accelerate funding to advance toward a potential Phase 1 clinical trial in the United States.
"We're thrilled to join forces with SGAustria in this game-changing Joint Venture,” said Chris Winter, CEO of Avant. “Merging our capital and forward-thinking strategy with their advanced biotech innovations, we're setting the stage for revolutionary diabetes therapies that have the potential to transform countless lives. This milestone represents a defining step for Avant as we commit to the advancement of regenerative healthcare."
This announcement completes Avant's June 2025 plans to create a new company to expand its interests in a diabetes development program offering significant treatment opportunities. SGAustria brings proprietary, clinically proven cell-encapsulation technology designed to protect, isolate, store, and transport living cells, with expertise in cell biology and GMP-grade manufacturing supporting commercialization efforts.
Avant's other advanced partnership, Klothonova, Inc., is a 50/50 joint venture with Singapore-based cell therapy pioneer Austrianova focusing on developing cell-based therapies utilizing encapsulated Klotho-producing cells targeting age-related diseases and anti-aging therapies. The program successfully completed its initial R&D proof of concept phase and is advancing to GMP-grade production for potential preclinical and clinical studies at Austrianova's ISO9001:2015 compliant facility.
The scientific foundation for Klotho-based therapies is widely considered compelling. Studies show higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lower Klotho levels had 31% higher mortality rates. Natural Klotho levels drop by 50% after age 40, creating vast and urgent therapeutic opportunities for this "longevity protein."
Both SGAustria and Austrianova utilize cell-encapsulation platforms backed by over 50 peer-reviewed publications representing decades of development studied for multiple therapeutic protein applications.
The potential market opportunity spans multiple therapeutic areas. The global Alzheimer's market is projected to reach $32.8 billion by 2033, cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. The cell-based therapy market could reach $44 billion globally, while diabetes affects over 500 million people worldwide, representing an urgent health crisis requiring innovative therapeutic solutions.
CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) presented new data at the North American Cystic Fibrosis Conference demonstrating that lower sweat chloride levels following CFTR modulator treatment correlate with improved clinical outcomes in cystic fibrosis patients, particularly in younger populations. Multiple abstracts showcased ALYFTREK's superior sweat chloride reductions compared to TRIKAFTA in Phase 3 trials, with pooled analyses revealing that participants initiating therapy at younger ages achieved greater CFTR function levels and experienced broad clinical benefits including improved lung function, respiratory symptoms, nutritional status and reduced pulmonary exacerbation rates.
The company's CFTR modulator portfolio now treats over 75,000 people with CF across more than 60 countries on six continents, representing approximately two-thirds of diagnosed CF patients eligible for modulator therapy. Vertex continues advancing its robust pipeline in cystic fibrosis while expanding into other serious diseases including neuropathic pain, kidney diseases, type 1 diabetes and myotonic dystrophy type 1.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) reported Q3 2025 financial results with total net product revenue of $171.0 million representing 63% year-over-year growth, driven by AUVELITY sales of $136.1 million (69% growth), SUNOSI revenue of $32.8 million (35% growth), and SYMBRAVO sales of $2.1 million in its first full quarter. The company recently submitted a supplemental NDA to the FDA for AXS-05 in Alzheimer's disease agitation, a serious condition affecting millions of patients representing a critical unmet medical need.
"Axsome posted strong revenue growth in the third quarter driven by contributions from all three of our marketed products," said Herriot Tabuteau, CEO of Axsome Therapeutics. "Our broad development pipeline continues to advance, and we recently submitted our supplemental NDA for AXS-05 for the treatment of Alzheimer's disease agitation, a serious condition affecting millions of patients in the U.S., and a critical unmet medical need."
The company plans to initiate multiple Phase 3 trials in Q4 2025 including solriamfetol in pediatric ADHD and MDD with excessive daytime sleepiness, AXS-05 in smoking cessation, and AXS-14 in fibromyalgia. Axsome believes its current cash of $325.3 million is sufficient to fund anticipated operations into cash flow positivity based on the current operating plan.
West Pharmaceutical Services, Inc. (NYSE: WST) launched its West Synchrony Prefillable Syringe System at CPHI Worldwide, offering a fully verified platform from a single supplier designed specifically for biologics and vaccines that will be commercially available in January 2026. The innovative system marks a significant shift in drug delivery solutions by providing comprehensive performance and regulatory data packages that accelerate syringe selection and streamline the path to market.
"Leaders in drug development face pressures to meet milestones efficiently amid complex challenges, amongst them, selecting prefillable syringes," said Andy Polywacz, President of Integrated Systems at West. "With West Synchrony prefillable syringe system, it enables pharmaceutical companies to streamline design, accelerate regulatory submission, and secures a reliable supply chain for combination products that meets quality and volume needs."
The platform includes single design verification and characterization packages, streamlined regulatory submission with one system-level drug master file, and flexible make-to-stock and make-to-order supply options with low minimum order quantities. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West delivers over 41 billion components and devices annually supporting the safe containment and delivery of life-saving medicines.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced FDA acceptance of the BLA resubmission for KRESLADI, a lentiviral vector-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I, with a PDUFA target action date of March 28, 2026. The submission is supported by positive clinical data from the global Phase 1/2 study demonstrating 100% overall survival at 12 months post-infusion with all primary and secondary endpoints met, substantial reductions in significant infections compared to pre-treatment levels, and no treatment-related serious adverse events.
"We value the continued dialogue with the FDA and believe the BLA moves Rocket closer to our goal of delivering a one-time gene therapy to patients facing the devastating effects of severe LAD-I," said Gaurav Shah, CEO of Rocket Pharma. "For these patients, survival beyond childhood is uncommon. Bone marrow transplant is currently the only treatment option, has substantial morbidity, mortality, and cost, and may not be available in time for these children."
The company is eligible for a Rare Pediatric Disease Priority Review Voucher should KRESLADI receive approval. Rocket's broader pipeline includes late-stage lentiviral vector-based programs for Fanconi Anemia and Pyruvate Kinase Deficiency, plus AAV vector-based cardiovascular programs for Danon Disease, PKP2-arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy.
Sources: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/
CONTACT:
Baystreet.ca
cs@baystreet.ca
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
--
SOURCES CITED
1. https://www.mordorintelligence.com/industry-reports/biologics-market
2. https://investor.westpharma.com/news-releases/news-release-details/west-synchronytm-prefillable-syringe-system-launches-cphi
3. https://www.fda.gov/news-events/press-announcements/fda-moves-accelerate-biosimilar-development-and-lower-drug-costs
4. https://www.cellandgene.com/doc/cell-gene-therapies-will-represent-a-continuation-of-fda-s-developments-0001
Related Stories
